ATP-binding cassette (ABC) proteins constitute one of the largest protein superfamilies and are present in all organisms from bacteria to human [
1,
2]. Prototypical ABC proteins are membrane-bound transporters coupling ATP hydrolysis to the translocation of substrates across biological membranes [
3,
4]. In addition to transporters, ABC proteins also comprise ion channels, regulators of ion channels, receptors, and proteins with roles in ribosome assembly and translation. The human genome has 48 genes encoding ABC proteins, of which 17 have been linked to hereditary diseases, including cystic fibrosis, adrenoleukodystrophy, Stargardt disease and disorders of cholesterol metabolism [
2,
5,
6].
ABC proteins share a conserved domain architecture. A functional transporter requires the cooperation of two transmembrane domains (TMD) and two cytosolic nucleotide binding domains (NBDs, also called ATP-binding cassettes). Eukaryotic ABC proteins are either full transporters combining all required domains in one polypeptide (2 TMDs and 2 NBDs), or half-transporters consisting of 1 TMD and 1 NBD that need to form homo- or heterodimers to constitute a functional pump. According to their domain architecture and sequence, metazoan ABC transporters are divided into subfamilies, of which seven (A to G) exist in human [
7]. An eighth subfamily (H) has been defined following the analysis of the
Drosophila melanogaster genome [
2]. The H subfamily is missing in mammals, but has one member in zebrafish [
8]. The members of subfamilies E and F are not transporters and differ from other ABC proteins in that they possess two NBDs but lack TMDs. ABCE proteins are inhibitors of RNAse L and involved in the assembly of the preinitiation complex [
9-
11], while ABCF proteins have roles in ribosome assembly and protein translation [
12,
13].
The first eukaryotic ABC transporter discovered was the human (h) drug efflux transporter MDR (multidrug resistance) P-glycoprotein (hABCB1/MDR1), the name of which reflects that its expression in cancers can cause a decreased cellular drug accumulation (initially referred to as drug permeability, 'P'), resulting in the resistance of tumours against chemotherapy [
14,
15]. Subsequent studies have identified further ABC proteins that are drug efflux pumps and can cause MDR in cancers, including the multidrug resistance associated protein (hABCC1/MRP1) [
16] and the breast cancer related protein (hABCG2/BCRP) [
17]. Drug efflux transporters are found in ABC subfamilies B, C and G [
18], and in normal tissues often show an apical expression in epithelia involved in excretion or forming boundaries of the body, reflecting their role in the biochemical defence against toxicants [
19]. ABC drug efflux transporters have a wide phylogenetic distribution and are found in vertebrates as well as in deuterostome invertebrates (sea squirt
Ciona intestinalis [
8]; sea urchin
Strongylocentrotus purpuratus [
20]), protostome invertebrates (nematode
Caenorhabditis elegans [
21]; fruitfly
Drosophila melanogaster [
2]), protozoans and yeast [
22,
23]. Homologous proteins are also present in plants, though their roles in multidrug efflux have not been firmly established [
24,
25].
The planktic crustacean
Daphnia is globally distributed and has central importance for the ecology of lakes and ponds. The currently accomplished sequencing of the
Daphnia pulex genome will thus enhance research in disciplines which traditionally have made use of daphnids, e.g., ecology, physiology, toxicology, population genetics and behaviour. Moreover, studies with an evolutionary perspective are further expected to benefit, because
Daphnia is not only the first crustacean, but also the first non-insect arthropod to have its genome sequence determined. The aim of this study was to provide a survey of the ABC transporter gene family of
Daphnia pulex. A complete or close to complete list of ABC transporters in
Daphnia will facilitate the identification of genes that play a role during the adaptation of
Daphnia to environmental toxicants. Furthermore, ABC genes have been suggested as biochemical factors contributing to the phenomenon of resistance against chemotherapeutics in parasites [
22,
26] and insects [
27,
28]. In the aquaculture industry, parasitic crustaceans constitute a problem of considerable economic importance. The potential development of resistances against therapeutics used to control the crustacean parasite sea louse (
Lepeophtheirus salmonis) in salmon farming is currently becoming a concern, and it has recently been proposed that ABC transporters in the sea louse could represent potential biochemical resistance factors to emamectin, a therapeutic used to control sea louse infestations in salmon [
29,
30]. At the same time, the sulfonylurea receptor has been suggested to represent the target for the chitin synthesis inhibitor diflubezuron [
31], a compound also used to treat sea lice infections. Thus, ABC transporters might have relevance in crustaceans both as biochemical defence mechanisms against toxicants, and as targets of toxicity.
From an evolutionary perspective, the wide distribution of ABC transporters capable of drug efflux transport suggests they are of ancestral origin. However, ABC subfamilies containing drug transporters (B, C, and G) also comprise proteins with other functions. For instance, the arguably best known drug efflux pump hABCB1/MDR1 belongs to the B subfamily that also contains mammalian transporters of bile salts and phospholipids, and yeast transporters of pheromones. Because of the lack of clear orthologous relationships between ABC proteins of the nematode worm
Caenorhabditis elegans and those of other genomes, it has been suggested that drug efflux pumps have evolved independently several times [
21]. The annotation of ABC transporters in the
Daphnia genome, provided by this work, represents an important resource for future biochemical, toxicological and physiological studies of ABC drug efflux transporters